# OnCo record keynote-042 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-042/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-042", "NCT02220894" ;
  schema:name "KEYNOTE-042"@en ;
  schema:description "KEYNOTE-042 extended pembrolizumab alone to any lung cancer with at least 1 percent PD-L1, but the survival gain came almost entirely from the tumours with 50 percent or more, so chemotherapy is still added for the rest."@en ;
  schema:url <https://onco.cc/trials/keynote-042/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02220894>, <https://doi.org/10.1016/S0140-6736(18)32409-7> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/pdl1-high-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pemetrexed/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/tps/>, <https://onco.cc/terms/pd-l1-testing/> ;
  onco:people <https://onco.cc/people/tony-mok/> .